Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-03-01
2005-03-01
Harris, Alana M. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S300000, C530S350000, C530S385000, C530S386000, C530S387900, C530S388100, C530S388150, C530S389100, C530S391300, C530S391700
Reexamination Certificate
active
06861509
ABSTRACT:
Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients.
REFERENCES:
patent: 6025157 (2000-02-01), Klein et al.
patent: O 846 764 (1998-06-01), None
patent: 1 010 432 (1998-06-01), None
patent: WO9516709 (1995-06-01), None
patent: WO 96 14861 (1996-05-01), None
patent: WO 97 11964 (1997-04-01), None
patent: WO 97 11965 (1997-04-01), None
patent: WO9718240 (1997-05-01), None
patent: WO 97 19693 (1997-06-01), None
patent: WO 97 19694 (1997-06-01), None
patent: WO 97 19695 (1997-06-01), None
patent: WO 97 30722 (1997-08-01), None
patent: WO9733912 (1997-09-01), None
patent: WO 97 34567 (1997-09-01), None
patent: WO 9740152 (1997-10-01), None
patent: WO 98 32458 (1998-07-01), None
patent: WO 98 36072 (1998-08-01), None
patent: WO 98 45708 (1998-10-01), None
patent: WO 98 46737 (1998-10-01), None
patent: WO 98 52591 (1998-11-01), None
patent: WO 98 53069 (1998-11-01), None
patent: WO 9854213 (1998-12-01), None
patent: WO 99 49039 (1999-09-01), None
patent: WO 99 50298 (1999-10-01), None
patent: WO 99 62332 (1999-12-01), None
Lederman, Seth et al. A Single Amino Acid Substitution In a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4. Moleuclar Immunology 28(11):1171-1181, 1991.*
Li, et al. Beta-Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities. Proc. Natl. Acad. Sci. USA 77(6):3211-3214, Jun. 1980.*
GenCore database. Amino acid sequence alignment between Applicants' SEQ ID No: 13 and Sequence 3 of U.S. Patent No. 6,025,157, issued Feb. 15, 2000.*
Jing et al. GDNF-Induced Actvation of the Ret Protein Tyrosine Kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124, Jun. 28, 1996.*
Amino acid database sheets. 1997.*
Tsuzuki et al. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10:191-198, Jan. 1995.*
Yan, Qiao, et al., “In vivo neutrotrophic effects of GDNF on neonatal and adult facial motor neurons,”Nature,373:341-344 (1995).
Vega, Q.C. et al., “Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis,”Proc. Natl. Acad. Sci. USA93:10657-10661 (Oct. 1996).
Baloh et al., “TrnR2, a Novel Receptor That Mediates Neurturin and GDNF Signaling through RET,” 1997, Neuron 18:793-802 (1997).
Beck et al., “Mesencephalic Dopaminergic Neurons Protected by GDNF from Axotomy-Induced Degeneration in the Adult Brain,” Nature 373:339-341 (1995).
Buj-Bello et al., “Neurturin Responsiveness Requires a GPI-Linked Receptor and the Ret Receptor Tyrosine Kinase,” Nature 387:721-724 (1997).
Creedon et al., “Neurturin Shares Receptors and Signal Transduction Pathways with Glial Cell Line-Derived Neurotropic Factor in Sympathetic Neurons,” Proc. Nat. Acad. Sci. USA 94:7018-7023 (1997).
Durbec et al., “Common Origin and Developmental Dependence on C-Ret of Subsets of Enteric and Sympathetic Neuroblasts,” Development, 122:349-358 (1996).
Durbec et al., “GDNF Signalling Through the Ret Receptor Tyrosine Kinase,” Nature, 381:789-793 (1996).
Edery et al., “Mutations of the RET Proto-Oncogene In Hirshsprung's Disease,” Nature, 367:378-380 (1994).
Eng et al., “The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease,” Seminars in Medicine of the Beth Israel Hospital, Boston, 335:943-951 (1996).
Gash et al., “Functional Recovery in Parkinsonian Monkeys Treated with GDNF,” Nature, 380:252-255 (1996).
Gattei et al., “Expression of the RET Receptor Tyrosine Kinase and GDNFR-alpha in Normal and Leukemic Human Hematopoietic Cells and Stromal Cells of the Bone Marrow Microenvironment,” Blood 89:2925-2937 (1997).
Henderson et al., “GDNF: A potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle,” Science, 266:1062-1064 (1994).
Hofstra et al., “A Mutation in the RET Proto-oncogene Associated with Multiple Endocrine Neoplasia Type 2B and Sporadic Medullary Thyroid Carcinoma,” Nature, 367:375-376 (1994).
Jing et al., “GDNF-Induced Activation of the Ret Protein Tyrosine Kinase is Mediated by GDNFR-alpha, a Novel Receptor for GDNF,” Cell, 85:1113-1124 (1996).
Klein et al., “A GPI-Linked Protein that Interacts with Ret to Form a Candidate Neurturin Receptor,” Nature 387:717-721 (1997).
Kotzbauer et al., “Neurturin, a Relative of Glial-Cell-Line-Derived Neurotrophic Factor,” Nature 384:467-470 (1996).
Lin et al., “GDNF: A Glial Cell Line Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons,” Science 260:1130-1132 (1993).
Lindsay, R. M., et al., “Neuron Saving Schemes,” Nature 373:289-290 (1995).
Lo, L., et al., “Postmigratory Neural Crest Cells Expressing c-RET Display Restricted Developmental and Proliferative Capacities,” Neuron 15:527-539 (1995).
Massague, J., “Crossing Receptor Boundaries,” Nature 382:29-30 (1996).
Moore, M.W., et al., “Renal and Neuronal Abnormalities in Mice Lacking GDNF,” Nature 382:76-79 (1996).
Oppenheim, R.W., et al., “Developing Motor Neurons Rescued from Programmed and Axotomy-Induced Cell Death by GDNF,” Nature 373:344-346 (1995).
Pachnis, V., et al., “Expression of the C-Ret Proto-Oncogene During Mouse Embryogenesis,” Development 119:1005-1017 (1993).
Pichel, J.G., et al., “Defects in Enteric Innervation and Kidney Development in Mice Lacking GDNF,” Nature, 382:73-76 (1996).
Robertson, K., et al., “The GDNF-RET Signalling Partnership,” TIG: 13:1-3 (1997).
Romeo, G., et al., “Point Mutations Affecting the Tyrosine Kinase Domain of the RET Proto-oncogene in Hirschsprung's Disease,” Nature 367:377-378 (1994).
Sanchez, M.P., et al., “Renal Agenesis and the Absence of Enteric Neurons in Mice Lacking GDNF,” Nature 382:70-73 (1996).
Santoro, M., et al., “Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B,” Science 267:381-383 (1995).
Schuchardt, A., et al., “Defects in the Kidney and Enteric Nervous System of Mice Lacking the Tyrosine Kinase Receptor Ret,” Nature, 367:380-383 (1994).
Suvanto, P., et al., “Cloing, mRNA Distribution and Chromosomal Localisation of the Gene for Glial Cell Line-Derived Neurotrophic Factor Receptor beta, a Homologue to GDNFR-alpha,” Human Molecular Genetics 6:1267-1273 (1997).
Tomac, A., et al., “Protection and Repair of the Nigrostriatal Dopaminergenic System by GDNF in vivo,” Nature, 373:335-339 (1995).
Trupp, M., et al., “Peripheral Expression and Biological Activities of GDNF, a New Neurotrophic Factor for Avian and Mammalian Peripheral Neurons,” Journal of Cell Biology 130:137-148 (1995).
Trupp, M., et al., “Functional Receptor for GDNF Encoded by the c-ret Proto-oncogene,” Nature 381:785-789 (1996).
Trupp, M., et al., “Complementary and Overlapping Expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF), c-ret Proto-oncogene, and GDNF Receptor-alpha Indicates Multiple Mechanisms of Trophic Actions in the Adult Rat CNS,” Journal of Neuroscience 17:3554-3567 (1997).
Van Heynngen, V., “One Gene-Four Syndromes,” Nature 367:319-320 (1994).
Van Weering, V., et al., “Glial Cell Line-derived Neurotrophic Factor Induces Ret-mediated Lamellipodia Formation,” Journal of Biological Chemistry, 272:249-254 (1997).
Worby, et al., “Glial Cell Line-derived Neurotrophic Neurotrophic Factor Signals through the RET Receptor and Activates Mitogen-activated Protein Kinase,” Journal of Biological Chemistry, 271:23619-23622 (1996).
Treanor, J.J.S. et al., “Characterization of a
Cate Richard L.
Hession Catherine
Sanicola-Nadel Michele
Worley Dane S.
Biogen Inc.
Biogen, Inc.
Harris Alana M.
LandOfFree
Antibodies to Ret and RetL3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to Ret and RetL3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to Ret and RetL3 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3394380